Tasimelteon

DB09071ApprovedInvestigationalSmall moleculeMelatonin Receptor Agonists

Tasimelteon is a melatonin receptor agonist used to treat Non- 24-Hour Sleep-Wake Disorder. Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness.

Chemical structure of Tasimelteon
Mechanism
Curator reviewed
Primary indication
Tasimelteon oral capsules are indicated for the treatment of non-24 hour sleep-wake disorder in adult patients and for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome in patients ≥16 years old.Curator reviewed · 3 structured indications
Formula / weight
C15H19NO2 · 245.322 g/mol (avg)
First approval
United States, 2014 · European Union, 2016
Code names
BMS-214,778 · VEC-162
Brand names
  • Hetlioz

Resolves to

Compound
UNIISHS4PU80D9CAS609799-22-6ChEMBLCHEMBL2103822ChEBI79042PubChem10220503KEGGD09388
Clinical / RWD
RxNorm1490468ATCN05CH03
Structure
InChIKeyPTOIAAWZLUQTIO-GXFFZTMASA-NSMILESCCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2
Targets
P48039MTNR1AP49286MTNR1B

What you can answer from here — as of March 10, 2022

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,782Drug interactionsStructured to mechanism, not free text
Sign in
22Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
7Marketed productsAcross 3 countries and 4 labellers
Sign in
1ATC codeIncluding every combination product, plus 15 drug categories
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tasimelteon, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In